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Declining blood pressure and intensification of blood
pressuremanagement among people over 80 years:
cohort study using electronic health records
Rathi Ravindrarajaha, Alex Dregana,b, Nisha C. Hazraa, Shota Hamadaa,
Stephen H.D. Jacksonc, and Martin C. Gulliforda,b
Background: Management of high blood pressure (BP) in
people over 80 years is controversial, but there is limited
information available concerning the uptake of
hypertension treatment at this age.
Objective: To evaluate use of antihypertensive drugs and
changes in SBP and DBP from 2001 to 2014 in men and
women aged 80 years and over.
Methods: Cohort study using primary care electronic
health records of 265225 participants from the UK Clinical
Practice Research Datalink. Records of BP and antihyper-
tensive medications were analysed. Linear trends were
estimated by frailty category in multiple regression models.
Results: Data were analysed for 116401 men and
148824 women. The proportion with BP recorded
increased from 51% in 2001 to 78% in 2014. The
proportion of patients prescribed antihypertensive
medications increased from 64 to 76%. Mean SBP
declined from 150 (SD 20)mmHg in 2001 to 135
(16)mmHg in 2014. In ‘fit’ participants, the decline in SBP
was 12.4 (95% confidence interval 11.9–13.0)mmHg/
decade in those treated for hypertension and 8.5
(7.8–9.1)mmHg in those not treated. The decline in SBP
was smaller as frailty increased. The proportion of all
participants with BP less than 140/90mmHg increased
from 14 to 44% in the study period.
Conclusion: In octogenarians, BP treatment has intensified
between 2001 and 2014. BP values have declined in both
treated and untreated participants, with a substantial
increase in the proportion achieving conventional BP
targets.
Keywords: 80 and over, aged, antihypertensive drugs,
blood pressure, frailty, hypertension, primary care
Abbreviations: AHT, antihypertensive therapy; BP, blood
pressure; CPRD, Clinical Practice Research Datalink; CVD,
cardiovascular diseases; eFI, electronic frailty index; FI,
frailty index; GP, general practitioner; EHR, electronic
health record; HSE, Health Survey for England; HYVET,
Hypertension in the Very Elderly Trial; NHANES, National
Health and Nutrition Examination Survey; NHS, National
Health Services; NRES, National Research Ethics Service
Committee; SPRINT, SBP Intervention Trial; US, United
States
INTRODUCTION
H
igh blood pressure (BP) represents a major con-
tributor to the global burden of disease, being a
leading risk factor for cardiovascular diseases
(CVDs) [1,2]. BP tends to increase with age [3], and the
highest incidence rates for cardiovascular events and great-
est cardiovascular mortality are observed at older ages [4].
Individuals aged 80 years and over represent the most
rapidly increasing section of the population [5]. In very
old people, hypertension remains a key risk factor for CVD,
but other health concerns including the accumulation of
deficits leading to frailty [6], functional and cognitive
decline, [7] dementia [8] and falls and fractures assume
increasing importance at this age [9].
BP management in very old people is controversial [9].
The results of the Hypertension in the Very Elderly Trial
(HYVET) suggested that good control of BP with antihy-
pertensive therapy (AHT) in people over 80 years of age
was associated with fewer strokes, less heart failure and
lower all-cause and cardiovascular mortality [10]. There was
no evidence for effect modification according to level of
frailty [11]. A recent trial of hypertension management in
community dwelling people aged 75 years and older, the
SBP Intervention Trial (SPRINT) showed that individuals
who were treated to attain a SBP goal less than 120mmHg
had 33% lower risk of CVD and about 32% lower risk of
mortality [12]. Nevertheless, critics argue that the suggested
benefits of antihypertensive treatment were observed in
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unusually healthy participants and that these results may
not be applicable to wider populations, which may experi-
ence multiple comorbidities and functional deficits, in
whom quality of life may be impaired and life expectancy
may be limited [13]. Some evidence suggests that there is a J-
shaped curve, with mortality risk being higher in individ-
uals with the lowest levels of BP [14,15]. We have recently
reported evidence that suggested that among octogenar-
ians, either very low and very high BP may be associated
with increased mortality risk [16]. Use of antihypertensive
medications may be associated with adverse outcomes,
such as an increased risk of falls and fractures [17]. These
are sometimes referred to as collateral risks of AHT [9].
Consequently, there exists uncertainty concerning the best
approach to managing BP in very old people [18].
Recently, there have been improving trends in hyper-
tension awareness, treatment and control in younger popu-
lations [19], but it is not known to what extent these trends
are shared by individuals aged 80 years and older. Most
population surveys sample only very small numbers of very
old people, and there may be additional barriers to
participation in older age possibly leading to nonresponse.
Participation in clinical trials may be limited by stringent
inclusion criteria and difficulties with recruitment and
retention from high levels of frailty and comorbidity [20].
This research is part of a wider project to evaluate
cardiovascular risk management in very old people. The
research draws on a database of primary care electronic
health records (EHRs) as a sampling frame that can yield a
large sample of individuals aged 80 years or older. We
included a sample of men and women aged 80 years and
over, registered with general practices in the United King-
dom between 2001 and 2014. We aimed to evaluate
changes in BP recording, in mean SBP and DBP values,
the prevalence of hypertension and changes in the use of
antihypertensive medications over this period.
METHODS
Data source
This study employed the Clinical Practice Research Datalink
(CPRD) as a data source. The CPRD is one of the world’s
largest databases of primary care EHRs including approxi-
mately 7% of UK general practices, with data collected from
1990 to present. The registered active population of about
7 million is generally representative of the UK population in
terms of age and sex [21]. Data collected into CPRD comprise
clinical diagnoses, records of BP and other clinical measure-
ments, prescriptions, results of investigations and referrals to
specialist services. This study received scientific and ethical
approval from the Independent Scientific Advisory Commit-
tee for CPRD studies (ISAC Protocol 13_151). The CPRD has
broad National Research Ethics Service Committee ethics
approval for observational research studies.
Study participants
A stratified random sampling approach was used to select
study participants. Individuals who had their 80th, 85th,
90th, 95th and 100th birthdays, whereas registered with
CPRD were identified and a random sample of up to 50 000
men and 50 000 women was drawn from each age stratum.
An open cohort of 265 225 participants who contributed
person time between 2001 and 2014 was included in the
present analysis; 231 721 (87%) patients had at least one
valid BP measurement during the study period. Partici-
pants’ person time was eligible to be included in the
analysis, whereas they were aged 80 and over and had a
valid SBP and DBP measurement in the year.
Study measures
For each study year between 2001 and 2014, we evaluated
themean value for SBP and DBP readings recorded for each
participant. Hypertension was defined as a SBP/DBP
greater or equal to 140 (SBP) or 90 (SBP)mmHg or current
treatment with antihypertensive medication. Antihyperten-
sive drug prescriptions were identified from prescription
records, and these were classified into four classes: A, drugs
acting on the renin–angiotensin system, including angio-
tensin-converting enzyme inhibitors and AT1 blocking
drugs; B, beta-blockers; C, calcium channel blockers; and
D, thiazide diuretics [22]. A further category of ‘Other’
antihypertensive drugs was defined, including centrally
acting drugs, alpha-blockers and vasodilators. Controlled
hypertension was defined as both SBP/DBP less than 140/
90mmHg.
Age, smoking, BMI and total serum cholesterol values
were selected as covariates. Smoking status was determined
from information on smoking status in patients’ clinical
records [23]. Patients’ smoking status was classified into
the categories ‘nonsmoker’, ‘current smoker’ or ‘ex-
smoker’. BMI records were classified into the categories
underweight (<18.5 kg/m2), normal weight (18.5–24.9 kg/
m2), overweight (25.0–29.9 kg/m2) and obese (30 kg/m2).
Total cholesterol (TC) values were grouped into the
categories less than 3.0, 3.0–3.9, 4.0–4.9, 5.0–5.9 and at
least 6.0mmol/l. The prevalence of comorbidity at the age
of 80 years was determined from analysis of Read medical
codes, and where appropriate drug product codes, for
diabetes mellitus, coronary heart disease, stroke, cancer,
chronic obstructive pulmonary disease, musculoskeletal
and connective tissue diseases and nervous system dis-
eases. Frailty status was assessed using a previously pub-
lished 36-item electronic frailty index (eFI) [24]. The eFI was
devised from the cumulative deficit frailty model with the
eFI score calculated by the presence or absence of indi-
vidual deficits as a proportion of the total possible.
Categories of fit, mild, moderate and severe frailty were
defined following Clegg et al. [24], but quantitative traits
(including BP values) were omitted.
Analysis
Descriptive statistics were used to describe baseline charac-
teristics. Mean SBP and DBP in each year were determined
from 2001 to 2014, and trends were plotted by sex and
treatment status. The class of antihypertensive drugs and
number of different classes of drugs prescribed were
plotted by study year from 2001 to 2014. Linear regression
models were fitted to estimate trends in BP values from
baseline to the latest measure before study end date or last
data collection date or death date. The results were pre-
sented as mean change per decade with 95% confidence
intervals (95% CIs). The analysis was further explored to
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study, the treatment effect on BP trends by frailty status.
Separate regression models was fitted or frailty status
classified as fit (frailty index 0.12), mild (frailty index
0.12–0.24), moderate (0.24–0.36) and severe (>0.36). All
analyses were adjusted for age, comorbidity, BMI
categories, cholesterol categories, classes and number of
antihypertensive drugs. Sensitivity analyses were carried
out to evaluate whether general practitioners extended
their BP recording to patients with lower BPs. In addition,
we divided general practices into quartiles of BP recording
in 2001 and the SBP and DBP trends were estimated in each
quartile of BP recording. Stata version 13.0 was used to
conduct all statistical analysis (Stata Corp.; College Station,
Texas, USA).
RESULTS
Table 1 presents the characteristics of the study participants.
The initial study sample included 265 225 participants
(116 401 men and 148 824 women) aged 80 years and over.
Mean age at entry to the study was 82.8 years for men and
84.5 years for women, whereas the mean ages at exit from
the studywere 88.0 and 90.1 years, respectively. There were
16% of men with five or more comorbidities compared with
11% of women. A greater proportion of men were current
smokers compared with women. Women were more likely
to have higher recorded TC values, with more women
having TC levels at least 6mmol/l. A larger proportion of
men than women were overweight (31 vs. 21%). Women
generally showed greater frailty than men (4.4% of women
vs. 3% of men were severe by eFI).
Table 2 presents changes in BP recording and BP manage-
ment over the study period. The proportion of participants
with BP readings in each year increased from 51% in 2001 to
78% in 2014. The proportion of all participants with con-
trolled BP (<140/90mmHg) increased from 14% in 2001 to
44% in 2014. The mean SBP declined from 149.8 (SD
19.6)mmHg in 2001 to 135.4 (15.9)mmHg in 2014, whereas
mean DBP declined from 79.8 (9.4)mmHg in 2001 to 72.7
(8.9)mmHg. The proportion of participants with BP
recorded and who were prescribed antihypertensive drugs
increased from 64% in 2001 to 76% to 2014. The prevalence
of hypertension decreased slightly from 89% in 2001 to 85%
in 2014. Individuals with a SBP less than 120mmHg and on
treatment increased from 2.9 to 10.6% over the study
period.
Figure 1 presents changes in BP treatment during the
study period from 2001 to 2014. Fig. 1a shows trends over
time in the number of different classes of antihypertensive
drugs prescribed. There was evidence of intensification of
AHT over time, with a decline in the proportion receiving
no AHT and an increase in the proportion prescribed
multiple classes of antihypertensive (AHT) drugs. The
proportion of patients receiving no treatment declined from
36 to 24%. The proportion receiving monotherapy (a single
class of antihypertensive drug) decreased from 33 to 31%.
The proportion receiving drugs from two different AHT
classes increased from 22 to 30%; from three different AHT
classes from 8 to 12%; and four or five different AHT classes
from 2 to 3%. Additional analysis revealed similar trends in
men and women and in 5-year age groups over the age of
80 years. Figure 1b presents changes in the use of different
classes of antihypertensive drugs from 2001 to 2014. The
proportion of participants prescribed drugs acting on the
renin–angiotensin system (A) increased from 24% in 2001
to 48% in 2014, whereas the proportion of patients pre-
scribed thiazide diuretics (D) declined from 30% to 19%.
There were modest increases in the proportions prescribed
beta-blockers (B) and calcium-channel blockers (C).
Figure 2 presents trends in mean SBP and DBP for men
and women by antihypertensive treatment status. SBP and
DBP decreased over time in both men and women and in
those receiving AHT and those not. Between 2001 and
2014, mean SBP decreased from 148 to 134mmHg in treated
men and from 143 to 132mmHg in untreated men. Similar
reductions were observed in women treated with antihy-
pertensive drugs and those not treated (Fig. 2). Women
generally showed higher BP values than men, in both the
treated and untreated groups. The gradient of decrease
appeared to be slightly greater in treated participants,
especially among women (Fig. 2). In subgroup analyses,
this association was similar in each 5-year age groups from
80 to 99 years.
Table 3 shows the results of linear regression analyses
exploring the association of SBP and DBP with year of
study. In patients who were classified as ‘fit’ (free of frailty),
SBP declined by approximately 12mmHg/decade
(12.4mmHg 95% CI 13.0–11.9) in those who treated and
by 8.5 (9.1–7.8)mmHg/decade in those who were not
treated for hypertension. Adjustment for covariates (smok-
ing, BMI, cholesterol and multimorbidity) had negligible
effect on these estimates. Trends were generally similar in
TABLE 1. Characteristics of study participants
Men (116401) Women (148824)
Age at entrya (mean, SD) 82.84.12 84.55.28
Age at exita (mean, SD) 88.04.9 90.15.6
Year at entry (mean, SD) 20054 20044
Year at exit (mean, SD) 20104 20104
BMI categories (kg/m2)
<18.5 1113 (1.0) 3401 (2.3)
18.5–25 33546 (28.8) 37 810 (25.4)
25–30 36201 (31.1) 31 401 (21.1)
30 11038 (9.5) 15 442 (10.4)
Not known 34503 (29.6) 60 770 (40.8)
Cholesterol categories (mmol/l)
<3 1272 (1.1) 376 (0.3)
3–4 10711 (9.2) 4503 (3.0)
4–5 22091 (19.0) 16 631 (11.2)
5–6 14622 (12.6) 21 635 (14.5)
6 5576 (4.8) 19 532 (13.1)
Not known 62129 (53.4) 86 147 (57.9)
Smoking status
None 49438 (42.5) 94 994 (63.8)
Yes 13 476 (11.6) 9388 (6.3)
Ex 46 149 (39.7) 32 360 (21.7)
Not known 7338 (6.3) 12 082 (8.1)
Frailty index categories
Fit 55 048 (47.3) 64 873 (43.6)
Mild 42 593 (36.6) 54 262 (36.5)
Moderate 15 266 (13.1) 23 144 (15.6)
Severe 3494 (3.0) 6545 (4.4)
Figures are frequencies (column percentage) except where indicated.
a‘Age at entry’ refers to age at start date of the study and ‘age at exit’ refers to age at
end date of the study period.
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men and women, but estimates were slightly higher in
women. Declines in BP were smaller in magnitude as level
of frailty increased; in participants with ‘severe’ frailty the
decline in SBP was about half that observed in ‘fit’ partici-
pants, and there was no difference in estimate between
treated and untreated participants at this level of frailty.
Similar patterns of association were observed for DBP but
changes in DBP were of smaller magnitude.
Sensitivity analysis showed that in the lowest quartile of
practices, 41% of fewer patients had BP recorded during
2001, whereas in the highest quartile 64% or more patients
had BP recorded during 2001. Estimated trends in SBP and
DBP were similar for general practices in each quartile of
BP recording.
DISCUSSION
Main findings
Patients aged 80 years and over experienced significant
intensification of BP management between 2001 and 2014.
The proportion of all patients aged 80 years and over
treated with antihypertensive drugs has increased from
two-thirds to three-quarters, whereas the proportion
treated with two or more classes of antihypertensive drugs
has increased from approximately one-third to nearly one
half. Consequently, about 90% of all individuals aged
80 years and over may be classed as hypertensive according
to the criterion of BP at least 140/90mmHg or treated with
antihypertensive drugs. During the same period, there has
been a substantial decline in SBP and DBP of between 10
and 12mmHg/decade for SBP and 3 to 5mmHg/decade for
DBP. This trend was apparent both in participants treated
with antihypertensive drugs and in those untreated. This
has been accompanied be a rapid increase in the pro-
portion of all participants whose BP meets the criterion
of less than 140/90mmHg for acceptable BP control.
Comparison with other studies
There is now increasing evidence of benefit from BP low-
ering over the age of 75 or 80 years. The findings of the
HYVET trial [25] have now been supported by recent
TABLE 2. Changes in mean blood pressure values and blood pressure management over time
Year
No. of
participants
Age
(meanSD)
BP recorded
(Freq.%)
Mean SBP
(mmHg)
Mean DBP
(mmHg)
Treated,
N (%)
Hypertensiona
(Freq.%)
BP controlledb
(Freq.%)
BP controlledc
(Freq.%)
2001 98214 86.14.8 50058 (51.2) 149.819.6 79.89.4 32 034 (64.0) 44644 (89.2) 7096 (14.2) 1445 (2.9)
2002 111017 86.14.8 62497 (56.5) 148.919.5 79.29.5 41 522 (66.4) 55587 (88.9) 10 219 (16.4) 2104 (3.4)
2003 119338 86.14.8 76120 (63.9) 147.319.3 78.49.4 51 698 (67.9) 67265 (88.4) 14 418 (18.9) 3114 (4.1)
2004 126676 86.14.8 94085 (74.4) 145.118.4 77.59.2 64 840 (68.9) 82411 (87.6) 20 702 (22.0) 4474 (4.8)
2005 128448 86.34.8 97131 (75.7) 143.217.7 76.69.1 69 301 (71.4) 84970 (87.5) 24 607 (25.3) 5310 (5.5)
2006 128438 86.44.8 98927 (77.1) 141.717.3 75.89.1 72 206 (73.0) 86334 (87.3) 28 561 (28.9) 6204 (6.3)
2007 127931 86.64.8 100901 (78.9) 140.717.0 75.38.9 74 656 (74.0) 87863 (87.1) 31 618 (31.3) 6922 (6.9)
2008 126891 86.74.8 100557 (79.3) 139.716.7 74.89.0 75 432 (75.0) 87430 (87.0) 34 093 (33.9) 7677 (7.6)
2009 124795 86.84.8 98907 (79.3) 138.916.6 74.39.0 75 009 (75.8) 86058 (87.0) 35 568 (36.0) 8051 (8.1)
2010 117366 87.14.8 93464 (79.7) 138.216.5 74.09.0 71 226 (76.2) 81134 (86.8) 35 003 (37.5) 8138 (8.7)
2011 108893 87.44.8 87176 (80.1) 137.516.4 73.68.9 66 414 (76.2) 75236 (86.3) 33 702 (38.7) 8091 (9.3)
2012 99785 87.64.9 79415 (79.6) 136.916.3 73.48.9 60 514 (76.2) 68393 (86.1) 32 042 (40.4) 7925 (10.0)
2013 86367 87.85.0 68896 (79.8) 136.115.9 73.08.8 52 302 (75.9) 58771 (85.3) 28 999 (42.1) 7094 (10.3)
2014 71003 87.85.2 54973 (77.5) 135.415.9 72.78.9 41 831 (76.1) 46792 (85.1) 24 110 (43.9) 5848 (10.6)
aHypertension (BP> 140/90mmHg or treated for hypertension).
bBP controlled (BP<140/90mmHg and treated for hypertension as percentage of all participants with BP recorded in year).
cBP controlled (SBP<120mmHg and treated for hypertension as percentage of all participants with BP recorded in year).
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FIGURE 1 Use of antihypertensive medications by year of study. (a) Numbers of
different classes of antihypertensive drugs prescribed. (b) Trends in utilization of
different classes of antihypertensive drugs including A, drugs acting on the renin–
angiotensin system; B, beta-blockers; C, calcium channel blockers; D, thiazide
diuretics and O, other.
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publication of the results of the SPRINT [12]. A European
Society of Hypertension–European Union Geriatric Medi-
cine Society Working Group [26] also endorsed the need for
more active BP management in very old people. Some
observational studies suggest that mortality may be higher
at low BP values, but a negative association of BP with
frailty category could account for this association [27–30].
Trends in BP among individuals aged 80 years and older
are comparable with data reported for adults of all ages
from the Health Survey for England [19]. Mean SBP among
men in England is reported to have decreased from
134mmHg in 1994 to 129mmHg in 2011, and for women
from 131 to 122mmHg [19]. In the US National Health and
Nutrition Examination Survey (NHANES), participants aged
80 years and over showed a decrease in mean SBP from
147mmHg in 1988–1994 to 140mmHg in 2005–2010. In the
Tromso study, SBP in middle age decreased by 10.6mmHg
in women and 4.5mmHg in men between 1979 and 2008.
They suggested that this was mainly due to improved life
style factors such as a reduction in smoking and salt intake
and an improvement in diet [31]. The present report reveals
comparable decreases in SBP and DBP but shows that
changes are broadly similar in men and women, in partici-
pants treated for hypertension as well as those not, and in
subgroups of age over 80 years. NHANES data report the
use of multiple classes of antihypertensive drugs increasing
from 37 to 48% between 2001 and 2010 [32–34], with
increasing utilization of all classes of antihypertensive
drugs. This is generally consistent with the recommen-
dations of guidelines for the general population and similar
to our finding that monotherapy for treatment of
hypertension has decreased over the study period
[35,36]. In the present study, women tended to have higher
recorded BP values than men, irrespective of treatment
status. A similar pattern of sex disparity in BP measurement
was noted in a Spanish study [37]. This finding appears to
support the view that men who reach older ages may in
some respects be healthier than their female counterparts
[38,39].
The prevalence of hypertension was modestly higher in
the present CPRD cohort compared with the sample of
community dwelling adults aged 80 years and over in the
NHANES study, with a prevalence of 76.5% [32] in the
United States. A similar prevalence of hypertension (74%)
was reported in the Framingham heart study among indi-
viduals aged 80 and over in the community [40]. A Spanish
study, which included over 300 patients aged 80 years and
over, reported the prevalence of hypertension to be 72.8%
[41].
Previous studies have related increased hypertension
treatment practices with a decline in mean SBP and DBP
[19,33,42], but only one previous study had focused on older
adults aged 80 years and over in theUnited States. The results
suggested that therewas an increase in awareness, treatment
and control of hypertension from 1988 to 2010 [32]. Our
results showing a decrease in both SBP and DBP in the
untreated group are consistent with the findings from the
Tromsø study, which showed a trend of BP reduction in
the entire population, suggesting awholepopulation change
potentially related to factors other than treatment [31].
The decrease in BP in the untreated groups may be
explained by public health initiatives undertaken in recent
155
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FIGURE 2 Trends in mean SBP and DBP in people aged 80 years or over from 2001 to 2014. Squares, women; circles, men; light symbols, treated with antihypertensive
drugs; and dark symbols, not treated with antihypertensive drugs.
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years to reduce and manage comorbidities by emphasizing
the benefits of weight loss, salt reduction, smoking cessa-
tion, healthy diet and exercise. There has been a major
reduction in salt consumption in the United Kingdom; salt
intake in United Kingdom has decreased by 1.4 g/day in
2000 to 8.1 g/day in 2011 [43]. This reduction in BP observed
among this elderly study populationmay be the result of the
initiatives set by National Service Framework for Older
People that promoted the health and well being of the
elderly by programmes led by the National Health Service
(NHS) with the help of the councils. This encouraged
increased physical activity, healthy eating, immunization
programmes for influenza, access to smoking cessation
programmes and other initiatives including providing sup-
port in terms of benefits for those facing poverty [44]. It may
also be that antihypertensive drug therapy has been intro-
duced at lower levels of BP over time.
Strengths and limitations
This study drew on a large, longitudinal and nationally
representative data resource. This allowed us to present
data for a very large sample of older adults, stratified by sex
and frailty status. We acknowledge several limitations of the
data. The number of general practices providing data
changed over time and both general practices and patients
entered and left the study over time, and this could have
contributed to changes in case-mix over the study period,
but analyses were adjusted for case-mix. BP readings were
recorded in clinical practice, and recordings were not made
using standardized methods. As BP, measurements were
carried out in clinical settings, ‘white coat hypertension’
might have contributed to higher BP readings [45]. BP
measurement methods may have changed over time, with
automated devices gradually replacing traditional mercury
sphygmomanometers, although this may have not biased
the data. Antihypertensive drug utilization estimates were
based on prescription records and not on prescriptions
dispensed or drugs taken. Confounding by indication
may be important in observational data, and this may
explain why BP values were higher for treated than
untreated participants.
In conclusion, there has been an increase in intensifica-
tion of BP treatment in the population aged 80 years and
over, with an increasing proportion now treated with
multiple classes of antihypertensive drugs. A substantial
decline in BP was observed over the past two decades. As a
result, the proportion of patients achieving the criterion of
BP less than 140/90mmHg has increased, which may lead
to improved cardiovascular outcomes [46]. It is well recog-
nized that treatment and control of hypertension in the
elderly should be placed in the context of increased comor-
bidity or frailty among older people [47]. Further research is
needed to understand in more detail the health outcomes of
intensified BP management in people over 80 years of age,
including the impact on their wellbeing.
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